Results 71 to 80 of about 21,815 (182)

A Single-arm Phase II Study Combining NLG207, a Nanoparticle Camptothecin, with Enzalutamide in Advanced Metastatic Castration-resistant Prostate Cancer Post-Enzalutamide

open access: yes, 2022
BACKGROUND: Despite the clinical efficacy of enzalutamide monotherapy in patients with advanced prostate cancer, therapeutic resistance and disease progression are inevitable. We proposed a study to evaluate NLG207, a nanoparticle-drug conjugate (NDC) of
Schellens, Jan H M   +37 more
core   +1 more source

Survival Outcomes by Frailty and Comorbidities in Veterans Treated With Abiraterone and Enzalutamide for Metastatic Castration‐Resistant Prostate Cancer

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Androgen receptor pathway inhibitors (ARPIs) such as abiraterone and enzalutamide are common therapies in the management of metastatic castration‐resistant prostate cancer (mCRPC). However, the comparative effectiveness of these oral ARPIs in frail and comorbid patient populations remains uncertain.
Meghana Yellanki   +6 more
wiley   +1 more source

Human Prostate Cell Lines: Derivation, Molecular Characteristics and Appropriate Use

open access: yesThe Prostate, EarlyView.
ABSTRACT Background Research on prostate cancer and benign prostatic hyperplasia depends on a small number of immortalized human cell lines established between 1977 and 2001, most of them from advanced metastatic disease. The cell lines differ from one another in androgen receptor status, prostate‐specific antigen secretion, p53 status, karyotype and ...
Hamza Abohamra, Keenau Mark Pearce
wiley   +1 more source

Table1_Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?.docx

open access: yes, 2022
Objective: To summarize the current therapeutic status using chemotherapeutic agent docetaxel and endocrine therapeutic agents (ARAT, abiraterone, orteronel or enzalutamide) for the treatment of metastatic castration-resistant prostate cancer (mCRPC ...
Dao-Sheng Luo (12098507)   +8 more
core   +1 more source

Cost-effectiveness and budget impact analysis of enzalutamide in comparison to abiraterone in treatment of metastatic prostate cancer resistant to castration in Iran

open access: yesBMC Urology
Introduction In recent years, enzalutamide and abiraterone have been widely used as treatments for metastatic castration-resistant prostate cancer (mCRPC). However, the cost-effectiveness of these drugs in Iran is unknown.
Zahra Goudarzi   +5 more
doaj   +1 more source

Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer

open access: yeseLife, 2017
Prostate cancer is driven by androgen stimulation of the androgen receptor (AR). The next-generation AR antagonist, enzalutamide, prolongs survival, but resistance and lethal disease eventually prevail.
Jianneng Li   +13 more
doaj   +1 more source

Androgen Receptor Expression in Urothelial Bladder Cancer—A Systematic Review and Meta‐Analysis

open access: yesANZ Journal of Surgery, EarlyView.
ABSTRACT Background Bladder cancer is a globally prevalent malignancy with a marked male predominance. Over the past decade, the androgen receptor has been investigated as a potential contributor to bladder cancer pathophysiology. Androgen receptor expression is most commonly assessed via immunohistochemistry, but its association with pathological ...
Alex Buckby   +3 more
wiley   +1 more source

Niclosamide Inhibits Androgen Receptor Variants Expression and Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer [PDF]

open access: yes, 2014
PURPOSE: Enzalutamide, a second-generation antiandrogen, was recently approved for the treatment of castration-resistant prostate cancer (CRPC) in patients who no longer respond to docetaxel.
Zhu, Yezi   +6 more
core   +1 more source

Dosing HIV integrase inhibitors with enzyme inducers: Convenience vs. control?

open access: yes
British Journal of Clinical Pharmacology, EarlyView.
Catia Marzolini, Saye Khoo
wiley   +1 more source

Comparative effectiveness of apalutamide‐, abiraterone‐, and enzalutamide‐based doublets in mHSPC

open access: yesBJU International, EarlyView.
Background and Objective Treatment of metastatic hormone‐sensitive prostate cancer (mHSPC) has evolved from androgen‐deprivation therapy (ADT) alone to combination therapy with androgen receptor pathway inhibitors. Although apalutamide (APA), abiraterone (ABI), and enzalutamide (ENZA) improve outcomes when added to ADT, direct comparative trials ...
Anikó Katalin Valikovics   +9 more
wiley   +1 more source

Home - About - Disclaimer - Privacy